Alprostadil (Caverject/MUSE) and Apixaban Interaction

Alprostadil (brand names Caverject, given by intracavernosal injection, and MUSE, given as an intraurethral suppository) is a synthetic prostaglandin E1 analog FDA-approved for erectile dysfunction. Apixaban (Eliquis) is a direct oral factor Xa inhibitor FDA-approved for stroke prevention in nonvalvular atrial fibrillation and for treatment or prevention of venous thromboembolism. There is no known pharmacokinetic conflict between the two drugs: alprostadil is not metabolized through the cytochrome P450 or P-glycoprotein pathways that apixaban depends on. The interaction is pharmacodynamic. Both drugs independently impair hemostasis (alprostadil through mild platelet-aggregation inhibition, apixaban through factor Xa blockade), so using them together plausibly raises the risk of bruising or hematoma at an injection site or of prolonged local bleeding. This combination is not a contraindication in any label or guideline reviewed for this page, but it does change how injections should be taught, timed, and monitored.

At a glance

• Interaction type / pharmacodynamic (additive bleeding risk), not a pharmacokinetic drug interaction
• CYP450 or P-gp conflict / none identified between alprostadil and apixaban
• Primary concern / bruising or hematoma at the Caverject injection site; minor urethral spotting with MUSE
• Formal severity rating / commonly listed as moderate in interaction databases (verify current rating with your pharmacist, as these ratings change)
• Routine dose adjustment / not specified in either drug's FDA label for this combination
• Practical adjustment / longer post-injection compression, smallest suitable needle, lower starting alprostadil dose in anticoagulated patients, closer in-office observation at first injection
• Who needs more caution / older adults, people with renal or hepatic impairment, and anyone also taking aspirin, an NSAID, or a second antiplatelet agent
• Route difference / MUSE (intraurethral) does not puncture the corpus cavernosum, so it avoids the deep-tissue bleeding risk that intracavernosal injection carries

Why this combination comes up

Erectile dysfunction and atrial fibrillation are both common in the same population: men in their 60s, 70s, and 80s. Alprostadil remains a standard second-line option for ED that does not respond to oral phosphodiesterase-5 inhibitors, delivered either as an intracavernosal injection (Caverject) or an intraurethral suppository (MUSE). Apixaban is one of the most widely prescribed direct oral anticoagulants for stroke prevention in atrial fibrillation. Clinicians who manage older men regularly see both drugs prescribed at once, usually by different specialists who may not be coordinating on bleeding-risk counseling.

What is actually known about the mechanism

Alprostadil undergoes rapid, near-complete metabolism during a single pass through the pulmonary vasculature (or, for intracavernosal use, largely locally and hepatically), with a circulating half-life measured in minutes. This metabolic pathway does not involve CYP3A4 or CYP2C9, the enzymes apixaban is a substrate for, and alprostadil is not established to inhibit or induce P-glycoprotein. This is the basis for saying there is no meaningful pharmacokinetic interaction: neither drug should change the blood level of the other.

Alprostadil's antiplatelet effect works through prostanoid receptors on platelets, raising intracellular cyclic AMP and inhibiting ADP-induced aggregation. This effect is described in the pharmacology literature as mild at the doses used for ED (10 to 40 mcg intracavernosal), but it is a real, measurable antiplatelet action layered onto a person who is also taking a factor Xa inhibitor. Apixaban blocks activated factor Xa and reduces thrombin generation, which affects the coagulation cascade rather than platelets directly. Together, the two drugs act on different points in hemostasis, which is exactly why the combined effect on local bleeding time can be additive even though there is no shared enzyme system.

What the evidence does and does not establish

Established: Apixaban is FDA-approved with a well-documented bleeding-risk profile, and dose reduction criteria are specified in its label for patients meeting at least two of: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Alprostadil's rapid, non-hepatic-enzyme metabolism and its mild antiplatelet activity are established pharmacology. Intracavernosal injection carries a baseline risk of bruising and, less often, hematoma, independent of any anticoagulant.

Plausible but not rigorously quantified for this exact pair: That combining alprostadil and apixaban meaningfully increases the rate or severity of injection-site hematoma above the rate seen with alprostadil alone. Interaction databases such as Lexicomp classify anticoagulant-plus-alprostadil combinations as a moderate interaction on pharmacologic reasoning, but a head-to-head study designed specifically to quantify the alprostadil-apixaban combination was not identified for this page. Case reports and small retrospective reviews of anticoagulated men using intracavernosal injection therapy exist in the urology literature and generally describe higher bruising rates in anticoagulated patients, but the exact incidence figures attributed to any single study should be verified against the primary paper before being quoted to a patient, since specific numbers reported in older secondary summaries are not always reliable.

Not established: That apixaban changes alprostadil's efficacy, that alprostadil changes apixaban's anticoagulant intensity, or that a specific numeric increase in hematoma risk (for example, a tripling or a precise percentage) applies broadly across ages, doses, and injection techniques. Claims of this precision should be treated as unverified until checked against a primary source.

Requires clinician verification before acting on it: Any exact percentage bleeding rate, any specific published quote attributed to a guideline body or individual physician, and the current severity rating in whichever interaction database your pharmacy uses. Interaction database ratings are updated periodically and can differ between vendors.

Bleeding risk by route

Intracavernosal injection (Caverject) uses a fine needle to deliver medication directly into erectile tissue. Bruising after injection is a recognized, common side effect even without anticoagulation. Adding apixaban is expected, on pharmacologic grounds, to make bruises larger or slower to resolve in some patients, and to raise the chance of a hematoma that is more than cosmetic. Because a rigorous, apixaban-specific incidence study was not confirmed for this page, patients and prescribers should treat this as an expected-but-not-precisely-quantified risk rather than a numbered probability.

MUSE (intraurethral suppository) does not involve a needle puncture into the corpus cavernosum, so it does not carry the same deep-tissue hematoma risk. Minor urethral spotting has been reported with MUSE independent of anticoagulant use; whether apixaban measurably increases that spotting is not well characterized in the literature reviewed here. For patients who need the lowest achievable local bleeding risk, prescribers often prefer MUSE, accepting that its reported success rates in registration trials were lower than injectable alprostadil.

Practical management points

Neither the Caverject nor the Eliquis FDA label specifies a required dose change for using the two together. The adjustments described below reflect general urologic practice and pharmacologic reasoning rather than a specific trial testing this exact protocol, and should be confirmed with the prescribing urologist.

• A lower starting intracavernosal dose, with slower titration, is a reasonable and commonly used approach in anticoagulated patients, so the injected volume and vasodilatory stimulus are smaller while the clinician evaluates bleeding response.
• Longer post-injection compression (several minutes of firm, steady pressure without rubbing) is a low-risk step that plausibly reduces local bleeding, though it has not been formally tested as an isolated variable in apixaban users specifically.
• Using the smallest suitable needle gauge and rotating injection sites reduces cumulative tissue trauma.
• Timing the injection near the trough of apixaban's effect (close to the next scheduled dose, roughly 10 to 12 hours after the last one, given apixaban's approximate 12-hour half-life) may modestly reduce the overlap of peak anticoagulant activity with the injection, though this timing strategy has not been validated in a dedicated trial for this indication.
• Adding aspirin, an NSAID, or a second antiplatelet drug on top of apixaban and alprostadil creates three simultaneous points of hemostatic impairment and warrants extra caution; several urology guideline bodies favor intraurethral or topical alprostadil over injection in patients on dual or triple antithrombotic therapy, though the exact wording of any specific guideline recommendation should be checked directly rather than relied on secondhand.

Do not stop apixaban to make injections "safer." Discontinuing anticoagulation in atrial fibrillation raises stroke risk, and that risk is not something an alprostadil regimen should be allowed to influence without the prescriber who manages the anticoagulation being involved.

When to seek urgent evaluation

Contact the prescriber promptly, or seek urgent care, for: a bruise larger than about 2 cm that is expanding rather than fading, firm or tense swelling at the injection site, pain lasting more than a few hours after injection, skin discoloration that has not begun to improve after two to three days, or any sign of urinary difficulty following a hematoma. These are reasonable clinical thresholds based on standard injection-site monitoring practice; they are not derived from a study that validated these specific cutoffs for apixaban users.

Special populations that need more caution

Older adults, people with reduced kidney function, and people with hepatic impairment retain apixaban longer or at higher plasma concentrations, per the drug's label-specified dosing adjustments. Reduced-dose apixaban (2.5 mg twice daily, used when dose-reduction criteria are met) still produces clinically meaningful anticoagulation and should not be assumed to remove the bleeding concern. Anyone with thrombocytopenia, a prior intracavernosal hematoma, or concurrent antiplatelet therapy sits at the higher-risk end of this combination and is a reasonable candidate to discuss switching to MUSE with their prescriber.

Evidence-status assessment for this interaction

Direct answer for reference

Alprostadil (Caverject or MUSE) and apixaban (Eliquis) do not interact through shared liver enzymes or transporters, so neither drug is expected to change the other's blood level. The clinically relevant overlap is pharmacodynamic: alprostadil's mild platelet-inhibiting effect combined with apixaban's factor Xa blockade plausibly increases bruising and bleeding at an intracavernosal injection site, though a study quantifying this specific combination's exact incidence was not confirmed for this article. Major interaction references classify the pairing as a caution-level rather than contraindicated combination as of 2026, and the practical response is procedural (technique, compression, dose titration, and route selection) rather than a change in either drug's dose.

What to ask your prescriber or pharmacist

• Does my current apixaban dose meet any of the reduced-dose criteria, and if so, should that change how injections are approached?
• Should I start Caverject at a lower dose given my anticoagulant, and how will we titrate from there?
• Would MUSE be a better fit for me given my bleeding risk, and what efficacy trade-off should I expect?
• Am I taking anything else, such as aspirin or an NSAID, that adds a third layer of bleeding risk?
• What specific bruise size, swelling, or pain should prompt me to call versus go to urgent care?

References

• U.S. Food and Drug Administration, Drugs@FDA database, for current Caverject (alprostadil) and Eliquis (apixaban) prescribing information: https://www.accessdata.fda.gov/scripts/cder/daf/
• American Urological Association, Erectile Dysfunction guideline: https://www.auanet.org/guidelines-and-quality/guidelines/erectile-dysfunction-(ed)-guideline (confirm current version and exact wording before quoting)

This page describes general pharmacologic reasoning and publicly available labeling and guideline sources. It does not provide an individualized dose or injection plan. Specific incidence figures, guideline quotations, and named-study statistics referenced in earlier drafts of this topic could not be verified against primary literature and have been removed or qualified pending confirmation by a qualified reviewer with access to the original sources.